EasyCookieInfo

Hamburg, Germany – November 13-15 Engage with Takis Biotech at BIO-EUROPE 2019

TDr Luigi Aurisicchio, CEO/CSO at Takis and Evvivax, will attend Bioeurope 2019. As Europe's largest life science partnering conference, BIO-Europe offers countless opportunities to engage with global life science partners. As key biotech, Takis will discuss with potential partners a number of available opportunities and services. The event brings together makers and investors within the life science industry to debate and to drive forward leading innovation.



This is an excellent opportunity to discuss Takis pipeline in one-to-one network meetings. Book your meeting with Luigi now!

To learn more: https://ebdgroup.knect365.com/bioeurope/?_ga=2.222724123.104266260.1571669222-1279262257.1532011842

26 September 2019 - Genomics and personalized medicine. Takis, the Italian excellence in biotechnology, challenges Europe!

The company of the Tecnopolo di Castel Romano in Rome is among the 7 finalists of the European Health Catapult. The final will be held on 2 and 3 December in Paris.

26 September, ROME - Takis with its advanced projects presented a personalized therapeutic vaccine against cancer at the European Health Catapult Initiative earning its place in the final. A result achieved thanks to the creation of a personalized therapeutic vaccine against cancer. It is therefore a new challenge that aims at personalized medicine, genomics and cellular therapies that many people see as a necessary path on which to invest.


The genome of each tumor, in fact, presents mutations that differ from patient to patient and generate abnormal proteins called neo-antigens, absent in healthy cells. The vaccine designed by Takis instructs the cells of the immune system to recognize tumor neo-antigens and to destroy only the cells that express them. But since every tumor is different, each patient needs a tailored therapy: the starting point is the sequencing of the tumor genome, which helps the researchers to build an ad hoc vaccine.

This is an innovative project, which Takis researchers are pursuing with competence and enthusiasm. And that at European Health Catapult, in which 42 start-ups participated in Europe, has already captured the interest of investors, confirming once again the excellence of Italian research in the oncology field.

"We are proud of this result - said Luigi Aurisicchio, CEO of Takis -. In recent years we have undertaken many projects and we have dedicated ourselves to developing increasingly targeted and effective therapies against cancer. The merit is, above all, of our researchers, who put passion into what we do day after day to help patients in oncology ".

Fabio Palombo, head of the research program, is of the same opinion: "Thanks to the growing knowledge in Immuno-Oncology, to the Next Generation Sequencing and to ever more effective technologies, it is now possible to think of approaches to personalized medicine inconceivable until a few years ago. And we Italians with our ideas and our imagination, we can make a huge contribution to this constantly evolving field ".

With his experience in innovative cancer therapies, Takis is the only Italian company to have achieved this goal, proving to be among the 7 best biotech companies in Europe. Thanks to an intense research activity, which has succeeded in intercepting the most advanced topics in the fight against cancer in recent years. Such as immunotherapy, which uses the immune system to fight cancer, giving life to potentially more effective therapies than traditional ones, and above all more targeted. The scientific production of Takis, in fact, appears to be increasingly oriented towards the future, which is that of precision medicine and tailored to the patient. A possibility that today, thanks to in-depth knowledge of the human genome, is becoming more and more concrete.

 

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse models demonstrated their ability to eliminate tumors in vivo, and to potentially prevent initial occurrence.

Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the protein telomerase (TERT), which is overexpressed in 85% of all mammalian cancers, whereas Takis S.R.L. designed a neoantigen-based cancer vaccine (TK), as a proof-of-concept of personalized immunology. For the studies, the TERT and TK based vaccines were produced in linear DNA form by LineaRx. Here is a summary of the recently completed studies performed in vivo:

Previous results from Phase 1 of the collaboration’s Joint Development Agreement (JDA) confirmed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase. The results reported herein are from the Phase 2 of the JDA using mice implanted with murine colon cancer.
In the prophylactic use of the telomerase vaccine, wherein vaccination is done before addition of tumor cell lines to the mice, transplanted tumors were cleared within 10 days.
In the therapeutic application using either TERT or TK linear DNA vaccine application, cancer cells were introduced and allowed to grow before administration of the vaccine. The successful reduction of total tumor mass was accomplished in conjunction with antibodies that targeted PD-1 and CTLA4. These antibodies, known as Checkpoint Inhibitors, are commonly used in oncology strategies that rely upon immunotherapy. In this setting the tumor cells were reduced significantly within 30 days.
The strategy of the Takis TK neoantigen vaccine uses unique multiple-target antigenic epitopes that have been identified from the tumor of a human patient. The linear DNA can utilize the genes for several of the most effective universal antigens such as TERT, or neoantigens that are more personalized to the patient.

“We know that immune system has a key role in fighting cancer” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide new therapies to our pet friends and human patients.”

For more information please see the Press Release from Applied DNA Sciences adnas

 

Trieste – 16-18 October 2019. Takis participating at Meet in Italy for Life Sciences

Dr Luigi Aurisicchio, CEO/CSO at Takis Biotech has been invited at the workshop “Opportunità per Healthcare Innovative Startup” by the organizers to share its experience as finalist at EIT  Health Catapult competition.

EIT Health is a network of the most important innovators in the healthcare field supported by the EU.
- € 90 million of investments attracted by Startups, 400 supported Startups, 21,000 trained professionals and graduates, 35 solutions introduced on the market. The Workshop has presented programs for innovative Healthcare Startups to more mature companies, such as Takis Biotech.

READ MORE

 

Expertscape: the research on cancer vaccines of Takis is an excellence in Italy

The American platform Expertscape has included our CEO and CSO, Dr. Luigi Aurisicchio, in the list of top experts on cancer vaccines in Italy. He ranks  second in the list, and he becomes first considering only biotech companies and Rome and central Italy. The capital city, in particular, ranks third in Italy, confirming itself as a geographical center of excellence in biotech research against cancer.

 

Expertscape, designed by researchers from the University of North Carolina, is an independent rating platform, which bases its ranking on the number of publications by specialists in the various fields of medicine. Especially, studies published in the last decade are taken into consideration as well as the quality of the magazine, the position of the author within the article and the type of scientific work.

Aurisicchio has published 23 articles over the past 10 years dedicated to therapeutic vaccines against cancer. Its scientific production ranges from human to veterinary medicine and in recent years appears increasingly projected towards the future, which is that of precision medicine and personalized therapies.

"Takis represents excellence in the panorama of Italian biotechnology companies - declared Aurisicchio - in recent years we have undertaken many projects and we have dedicated ourselves to developing increasingly targeted and effective therapies against cancer. The merit is also and of our researchers, who put passion into what we do day after day to help patients in oncology ".

Congratulations to Luigi Aurisicchio for this prestigious award.

Link to Expertscape: http://www.expertscape.com/ex/cancer+vaccines/c/it

1 August 2019 – Takis awarded with the SME Instrument Phase 1

We are proud to announce that Takis biotech has been awarded with the SME Instrument Phase 1(ot EIC accelerator)  for its program on Neo-Antigen cancer vaccine, TK-Neo. The aim of the instrument is to fund disruptive ideas and transform them into concrete innovative solutions with European and global impact. The outcome of a phase 1 project is a feasibility report, including a more elaborated business plan.

The EIC Accelerator (SME Instrument) is a public funding programme that funds risk innovation in small businesses. It funds market-creating innovation in disruptive small businesses that have significant growth potential and global ambitions. The EIC Accelerator (SME Instrument) is part of Horizon 2020 – the EU's 80 billion € funding programme for Research and Innovation for 2014-2020.

Only the most innovative companies get selected. Until now, out of over 50.000 applicants 4500 companies have been funded. This shows how intense the competition is under the programme and demonstrates the high quality of the proposals funded. 25% of the companies funded under the EIC SME Instrument are in the 10% fastest growing companies in Europe according to Venture Radar.

We believe that TK-NEO has all the features for providing new therapies and changing cancer patients’ life!

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958